author-photo

Stacey Hubay

11

Papers

57

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour mutation burden (pTMB): A Canadian Cancer Trials Group (CCTG) study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cabazitaxel in docetaxel-pretreated metastatic castration resistant prostate cancer (mCRPC): Canadian experience.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone

2016 Cuaj-canadian Urological Association Journal
Show All
- Source
- Cite
- Save
Citations (11)
A retrospective analysis of clinical factors influencing response to treatment with cabazitaxel in patients with metastatic castration resistant prostate cancer.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.

2007 BMC Health Services Research
Show All
- Source
- Cite
- Save
Citations (34)